Leerink Partners analyst, Geoffrey Porges, reiterated his Outperform rating on shares of Regeneron Pharma (NASDAQ: REGN) as expectations appear to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE